WINT vs. ACXP, SLXN, HCWB, CHRO, PRTG, OBSV, GTBP, CVM, APLM, and SBFM
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Acurx Pharmaceuticals (ACXP), Silexion Therapeutics (SLXN), HCW Biologics (HCWB), Chromocell Therapeutics (CHRO), Portage Biotech (PRTG), ObsEva (OBSV), GT Biopharma (GTBP), CEL-SCI (CVM), Apollomics (APLM), and Sunshine Biopharma (SBFM). These companies are all part of the "pharmaceutical products" industry.
Windtree Therapeutics vs. Its Competitors
Windtree Therapeutics (NASDAQ:WINT) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.
Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
Windtree Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.38, indicating that its share price is 238% less volatile than the S&P 500.
Windtree Therapeutics' return on equity of -362.76% beat Acurx Pharmaceuticals' return on equity.
Windtree Therapeutics currently has a consensus target price of $350.00, indicating a potential upside of 59,021.62%. Acurx Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 2,522.95%. Given Windtree Therapeutics' higher possible upside, research analysts clearly believe Windtree Therapeutics is more favorable than Acurx Pharmaceuticals.
In the previous week, Windtree Therapeutics had 6 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 8 mentions for Windtree Therapeutics and 2 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.62 beat Windtree Therapeutics' score of 0.58 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.
29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 0.3% of Windtree Therapeutics shares are owned by insiders. Comparatively, 26.0% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Acurx Pharmaceuticals received 14 more outperform votes than Windtree Therapeutics when rated by MarketBeat users. Likewise, 94.44% of users gave Acurx Pharmaceuticals an outperform vote while only 37.50% of users gave Windtree Therapeutics an outperform vote.
Summary
Acurx Pharmaceuticals beats Windtree Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:WINT) was last updated on 6/14/2025 by MarketBeat.com Staff
